In addition to IMIDs (immunomodulatory agents) and PIs (proteasome inhibitors), daratumumab, an anti-CD38 antibody initially approved for relapsed/refractory patients, is now moving into the frontline setting for newly diagnosed multiple myeloma, therefore adding a third gold standard in the newly diagnosed multiple myeloma therapeutic paradigm [1, 2]. Here, CD38 is linked to plasma cell myeloma.